This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NameExatecan
Accession NumberDB12185
TypeSmall Molecule
GroupsInvestigational
Description

Exatecan has been used in trials studying the treatment of Sarcoma, Leukemia, Lymphoma, Lung Cancer, and Liver Cancer, among others.

Structure
Thumb
SynonymsNot Available
External IDs DX-8951 / DX-8951f
Product Ingredients
IngredientUNIICASInChI KeyDetails
Exatecan MesylateD2VJ1CC26Q 197720-53-9FXQZOHBMBQTBMJ-MWPGLPCQSA-NDetails
ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIIOC71PP0F89
CAS number171335-80-1
WeightAverage: 435.455
Monoisotopic: 435.159434363
Chemical FormulaC24H22FN3O4
InChI KeyZVYVPGLRVWUPMP-FYSMJZIKSA-N
InChI
InChI=1S/C24H22FN3O4/c1-3-24(31)14-6-18-21-12(8-28(18)22(29)13(14)9-32-23(24)30)19-16(26)5-4-11-10(2)15(25)7-17(27-21)20(11)19/h6-7,16,31H,3-5,8-9,26H2,1-2H3/t16-,24-/m0/s1
IUPAC Name
(10S,23S)-23-amino-10-ethyl-18-fluoro-10-hydroxy-19-methyl-8-oxa-4,15-diazahexacyclo[14.7.1.0^{2,14}.0^{4,13}.0^{6,11}.0^{20,24}]tetracosa-1(24),2(14),6(11),12,15,17,19-heptaene-5,9-dione
SMILES
CC[[email protected]@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=C(F)C(C)=C4CC[[email protected]](N)C3=C14)C2=O
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Exatecan.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Exatecan.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Exatecan.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Exatecan.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Exatecan.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Exatecan.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Exatecan.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Exatecan.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Exatecan.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Exatecan.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Exatecan.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Exatecan.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentBrain and Central Nervous System Tumors / Malignant Lymphomas / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentLeukemias / Myelodysplastic Syndromes1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
2CompletedTreatmentCervical Cancers1
2CompletedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
2CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer / Liver Cancer1
2CompletedTreatmentLiver Cancer1
2CompletedTreatmentLung Cancers1
2CompletedTreatmentMalignant Neoplasm of Pancreas1
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentSarcomas3
3CompletedTreatmentMalignant Neoplasm of Pancreas1
Properties
StateNot Available
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.221 mg/mLALOGPS
logP1.67ALOGPS
logP1.55ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)11.71ChemAxon
pKa (Strongest Basic)9.52ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area105.75 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity115.8 m3·mol-1ChemAxon
Polarizability45.45 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as camptothecins. These are heterocyclic compounds comprising a planar pentacyclic ring structure, that includes a pyrrolo[3,4-beta]-quinoline moiety (rings A, B and C), conjugated pyridone moiety (ring D) and one chiral center at position 20 within the alpha-hydroxy lactone ring with (S) configuration (the E-ring).
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassCamptothecins
Sub ClassNot Available
Direct ParentCamptothecins
Alternative ParentsHaloquinolines / Pyranopyridines / Pyridinones / Aralkylamines / Aryl fluorides / Benzenoids / Tertiary alcohols / Heteroaromatic compounds / Amino acids and derivatives / Lactones
SubstituentsCamptothecin / Haloquinoline / Pyranopyridine / Quinoline / Aralkylamine / Pyridinone / Aryl fluoride / Aryl halide / Benzenoid / Pyridine
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Drug created on October 20, 2016 15:33 / Updated on September 01, 2017 12:18